Teprotumumab

Teprotumumab is a fully human antibody developed by Genmab under our collaboration with Roche. Teprotumumab targets the Insulin-like Growth Factor-1 Receptor (IGF-1R), which is a well validated target. Clinical development of teprotumumab in Graves' orbitopathy (thyroid eye disease) will be conducted by Horizon Pharma, who acquired River Vision Development Corporation, which licensed teprotumumab from Roche. Teprotumumab has been granted Orphan Drug Designation by the US FDA.

Back to top

Graves' orbitopathy is an autoimmune condition that is most commonly associated with hyperthyroidism, a disorder of the thyroid gland. Symptoms of Graves' orbitopathy include dry, watery, red eyes, double vision and other vision problems. Teprotumumab is being investigated in a Phase II study to treat Graves' orbitopathy. For more information on these studies, visit clinicaltrials.gov.

Back to top